PRM-151: Clinical Trials

5 trials of PRM-151, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 2 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 32Terminated 2
Phase 11Completed 1

Follow PRM-151: new trials by email Literature Review of PRM-151 trials Research Report on PRM-151

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
PRM-151 (Zinpentraxin Alfa) - Idiopathic Pulmonary Fibrosis
Phase 3TerminatedHoffmann-La Roche1172021-08-302024-05-16
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
PRM-151 (Zinpentraxin Alfa), Placebo - Idiopathic Pulmonary Fibrosis
Phase 3TerminatedHoffmann-La Roche6652021-03-192024-04-18
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
PRM-151, placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedHoffmann-La Roche1172015-09-012022-05-02
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
PRM-151, Placebo - Idiopathic Pulmonary Fibrosis
Phase 1CompletedHoffmann-La Roche212011-03-292022-04-20
PRM-151 in the Prevention of Scarring Following Trabeculectomy
PRM-151, Placebo - Glaucoma
Phase 2CompletedHoffmann-La Roche1242010-06-142022-04-28

Conditions studied

Idiopathic Pulmonary Fibrosis (4)  ·  Glaucoma (1)  ·  Pulmonary Fibrosis (1)

Sponsors

Hoffmann-La Roche (5)

Countries

Netherlands (5)  ·  Czechia (4)  ·  United States (4)  ·  Belgium (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  Argentina (2)  ·  Australia (2)  ·  Canada (2)  ·  China (2)  ·  Denmark (2)  ·  France (2)  ·  Greece (2)  ·  Hong Kong (2)

Top investigators

Bernt van den Blink, MD, PhD (1)  ·  Jeffrey Edelson, MD, FRCPC, MHSc (1)  ·  John Getsy, DMD, DO (1)

Results publications

PMID 36724330, PMID 26869678, PMID 29800034, PMID 31122893, PMID 35597980, PMID 38354066, PMID 39761005

NIH funding

2009 (1), 2014 (1)